Tests for Suspected Alzheimer's Disease: What a Memory Clinic Needs to Establish

A memory assessment may lead to discussion of cognitive testing, MRI, blood biomarkers, PET, or a lumbar puncture. This can sound like a list that every patient must complete. In practice, the investigation should follow the question being asked. First, is there a meaningful change in cognition or everyday functioning? Next, what could explain it? Finally, would additional evidence change treatment or care? Evaluation for an amyloid-directed medicine introduces further requirements. Understanding these purposes can make the process less confusing and help a family avoid paying for tests that do not answer a new question. NIA guide to diagnosis

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The history is an essential part of the diagnostic work, even when sophisticated tests are available. Describe when the difficulty began, whether it has progressed gradually or fluctuated, and which familiar activities are now harder. A dated example of repeatedly making the same bank transfer is more useful than a general statement that memory is poor. Include what help was needed and whether there was a consequence, such as a missed medicine or becoming lost.
Blood tests measuring phosphorylated tau and other proteins have made evaluation of Alzheimer's pathology more accessible. The 2025 specialist-care guideline distinguishes tests suitable for triage from those meeting the higher performance requirements for confirmation. It emphasizes objective cognitive impairment, the clinical context, and the substantial variation among assays. A test is not reliable simply because its name contains p-tau or because a different product achieved good accuracy in a published study. 2025 blood biomarker guideline
For a cross-border consultation in China, share the symptom timeline, full laboratory reports, previous cognitive assessments, and usable imaging files before travel where the service permits. Ask which investigations can be accepted and why any repetition is necessary. Long travel and consecutive appointments can be tiring, so the schedule should reflect the patient's capacity rather than the convenience of completing a package in one day.

Quick answer

Full guide

Start with an account of real changes

The history is an essential part of the diagnostic work, even when sophisticated tests are available. Describe when the difficulty began, whether it has progressed gradually or fluctuated, and which familiar activities are now harder. A dated example of repeatedly making the same bank transfer is more useful than a general statement that memory is poor. Include what help was needed and whether there was a consequence, such as a missed medicine or becoming lost.

The patient and care partner may notice different things. The patient may describe effortful word finding or anxiety, while a relative has observed repeated questions or errors with household tasks. These accounts can complement one another. Allow the patient to speak, and arrange an appropriate way for the family to add information. Bring a complete medicine list, including over-the-counter sleep or allergy products and supplements. Recent illness, hospital admission, alcohol use, mood, sleep, hearing, and vision are relevant to interpretation. DETeCD-ADRD diagnostic recommendations

An abrupt change in attention or awareness is a different situation from a routine appointment for gradually progressive forgetfulness. New confusion during illness, or a sudden neurological deficit, should be assessed promptly rather than left for an overseas memory consultation. An existing Alzheimer's diagnosis does not explain every new symptom that occurs afterward.

Cognitive assessment measures performance and function

Brief instruments sample abilities such as learning, attention, language, orientation, and planning. They help identify concerns and determine whether more detailed neuropsychological testing is needed. They do not directly identify amyloid pathology. A low score cannot distinguish every cause of impairment, and a reassuring score does not necessarily resolve a convincing history of decline in a highly capable person.

Tell the assessor about the patient's preferred language, education, literacy, and sensory difficulties. Bring glasses or hearing aids where needed. Fatigue and unfamiliar instructions can affect performance. For a patient visiting China, suitable language assessment should be arranged in advance; simply translating a few words during an unsuitable test may not preserve its validity. Family members should not coach answers during the assessment or repeatedly rehearse an identical online test beforehand. NICE assessment recommendations

The assessment also needs to establish how independently the person manages daily life. The relevant comparison is with their previous responsibilities and abilities. Someone who never handled finances should not be considered impaired merely because they cannot now manage a complex investment account. Conversely, a person may perform well in casual conversation while requiring increasing help with their own familiar work. This functional context helps distinguish mild cognitive impairment from dementia and guides immediate support.

Routine laboratory tests look for contributing conditions

Depending on the clinical context, initial investigations commonly include a blood count, metabolic and kidney or liver measures, electrolytes, glucose, thyroid function, and vitamin B12. Other tests are selected when the history or examination raises a particular concern. A tiered approach avoids ordering uncommon infection, immune, or genetic investigations indiscriminately. Previously available results may be useful if sufficiently recent and relevant.

These blood tests serve a different purpose from Alzheimer's biomarkers. They can reveal a treatable problem that contributes to cognitive symptoms or worsens an underlying disorder. Identifying low B12 or abnormal thyroid function does not automatically establish that it explains the whole illness. Follow-up may still be needed after correction. Similarly, a routine panel without abnormal flags cannot exclude a neurodegenerative disease. The clinician should explain which finding changes management and which is incidental rather than leaving the family to interpret a collection of arrows.

Structural imaging examines the brain's anatomy

MRI can show patterns of tissue loss, vascular injury, microbleeds, or other structural abnormalities. These findings help the clinician consider likely causes and possible coexisting disease. Hippocampal atrophy is not unique to Alzheimer's, and an early scan without obvious atrophy does not rule it out. The pattern and extent matter, as do age, symptoms, and the course of the illness.

CT may provide structural information when MRI is unavailable or unsuitable in the general diagnostic assessment. This does not make CT interchangeable with the MRI required to assess and monitor ARIA during amyloid antibody treatment. Tell the imaging service about implants, possible metal fragments, difficulty lying flat, or severe claustrophobia before the appointment. Device-specific safety checks are more useful than assuming every implant prohibits MRI. Diagnostic guideline, Lecanemab MRI requirements

If a scan has already been performed elsewhere, send the images as well as the report. A short written conclusion may not reveal whether the necessary sequences were acquired. Repeating imaging may be justified by a change in symptoms or inadequate technical information, but the receiving team should be able to explain the reason. A scan date alone cannot determine whether the study is suitable for a particular treatment decision.

Blood biomarkers require method-specific interpretation

Blood tests measuring phosphorylated tau and other proteins have made evaluation of Alzheimer's pathology more accessible. The 2025 specialist-care guideline distinguishes tests suitable for triage from those meeting the higher performance requirements for confirmation. It emphasizes objective cognitive impairment, the clinical context, and the substantial variation among assays. A test is not reliable simply because its name contains p-tau or because a different product achieved good accuracy in a published study. 2025 blood biomarker guideline

Regulatory developments also need to be read precisely. The FDA's first clearance of an Alzheimer's blood test in 2025 concerned the Lumipulse plasma ratio assay as an aid to assessment, rather than population screening or a stand-alone diagnosis. In August 2026, Roche announced US clearance of Elecsys pTau217 for people aged 55 and above with signs, symptoms, or complaints of cognitive decline in primary and specialty care. The latter has positive, intermediate, and negative result categories, and its stated use does not establish prediction of future dementia or monitoring of treatment effects. Neither US announcement establishes Chinese authorization or local hospital adoption. FDA announcement, Roche August 2026 announcement

An intermediate result is not a final diagnosis halfway between health and disease. It indicates uncertainty within that assay's decision system. The next step might be another validated method, cerebrospinal fluid testing, imaging, or specialist review, depending on what remains unresolved. A negative result may make Alzheimer's pathology less likely without explaining the patient's symptoms. A positive result still needs to be related to clinical findings and any other conditions present.

Quality updates matter after regulatory clearance. In 2026, the FDA published a recall record for Lumipulse-related products because falsely elevated ratios could produce incorrect positive or indeterminate classifications. Laboratories must check the actual products, component lots, and applicable correction notice, with clinical review of potentially affected previous results. This is not a reason to declare every Alzheimer's blood test invalid, nor does the US record by itself establish a recall in China. FDA correction and recall record

Ask which kind of PET is proposed

Amyloid PET, tau PET, and FDG-PET are not different names for the same examination. They provide information about different biological or metabolic processes. A result from a general metabolic brain scan should not be relabelled as an amyloid result. The ordering clinician should explain which tracer is being used and what decision the finding could change.

The updated Alzheimer's Association and SNMMI appropriate use criteria assess PET in specific clinical scenarios. They support selecting imaging according to diagnostic uncertainty and its expected effect on management. The value of another scan depends partly on what is already known. Ask about preparation, the length of the appointment, and when interpretation will be available. PET uses a radioactive tracer for assessment; it does not irradiate away Alzheimer's pathology or constitute treatment. 2025 amyloid and tau PET appropriate use criteria

Consider cerebrospinal fluid testing when it answers a useful question

Cerebrospinal fluid biomarkers can support assessment of Alzheimer's pathology, and lumbar puncture may also help investigate alternative diagnoses. It is not a compulsory step for every person attending a memory clinic. The decision should compare the information expected, available alternatives, existing results, and procedural considerations. A person who is worried about the procedure should be offered an explanation rather than simply redirected to an expensive test with a different purpose.

Before a lumbar puncture, disclose anticoagulant or antiplatelet treatment, bleeding problems, infection concerns, and relevant spinal history. The clinical team decides whether medicines need adjustment and how this can be done safely. The service should explain what to expect afterward and when headache or other symptoms warrant contact. Sample handling and laboratory methods affect biomarker interpretation, so numbers from different hospitals should not be compared without the units, assay information, and reference ranges. Alzheimer's Association medical testing information

Genetic results answer a separate set of questions

APOE is relevant to Alzheimer's risk and to discussion of ARIA risk with certain treatments. It does not establish the cause of a person's current cognitive symptoms on its own. Earlier onset or a pattern suggesting a familial disorder may lead to specialist consideration of genes such as APP, PSEN1, or PSEN2. That is a different process from obtaining a consumer susceptibility report. Genetic counselling helps clarify what a result could mean for the patient and relatives. NIA discussion of Alzheimer's and genetics

Before testing, discuss why the result is needed, what the patient wants to know, and how it may affect care. A negative susceptibility result cannot promise lifelong protection, and a positive one does not provide a reliable individual date of future symptoms. If a result would not change current management, it is reasonable to discuss whether testing now is useful. Treatment-related genetic assessment should still include these communication issues.

Finish the process with an explanation and a next step

For a cross-border consultation in China, share the symptom timeline, full laboratory reports, previous cognitive assessments, and usable imaging files before travel where the service permits. Ask which investigations can be accepted and why any repetition is necessary. Long travel and consecutive appointments can be tiring, so the schedule should reflect the patient's capacity rather than the convenience of completing a package in one day.

Arrange a visit to discuss the results together. The outcome should be an understandable account of the most likely diagnosis, remaining uncertainty, current functional needs, and what happens next. A minor abnormality does not always require a new medicine, and an unresolved diagnosis does not prevent attention to sleep, safety, medication management, or caregiver support. The purpose of investigation is to improve decisions for the person, not merely to accumulate a larger file of reports.